臨床外科78巻12号

2023年11月発行

特集 胃癌に対するconversion surgery—Stage Ⅳでも治したい！ 総論

Conversion surgeryを誘導するための化学療法レジメンとは

著者： 大沼啓之¹

所属機関： ¹札幌医科大学医学部腫瘍内科学講座

ページ範囲：P.1313 - P.1318

【ポイント】
◆胃癌においても奏効割合とconversion達成率は相関する可能性がある．
◆conversion達成には標準治療レジメンのほか，三剤併用療法やタキサン腹腔内投与療法も選択肢となりうる．
◆レジメンの選択においては強力なsurvival benefitを有するconversion surgery達成を見据えた視点を忘れてはならない．

参考文献

1）日本胃癌学会（編）；胃癌治療ガイドライン医師用2021年7月改訂，第6版．金原出版，2021

2）Saito M, Kiyozaki H, Takata O, et al：Treatment of stage Ⅳ gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients. World J Surg Oncol 12：406, 2014

3）Fukuchi M, Ishiguro T, Ogata K, et al：Prognostic role of conversion surgery for unresectable gastric cancer. Ann Surg Oncol 22：3618-3624, 2015

4）Kinoshita J, Fushida S, Tsukada T, et al：Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage Ⅳ gastric cancer. Eur J Surg Oncol 41：1354-1360, 2015

5）Maeda O, Matsuoka A, Miyahara R, et al：Modified docetaxel, cisplatin and capecitabine for stage Ⅳ gastric cancer in Japanese patients：a feasibility study. World J Gastroenterol 23：1090-1097, 2017

6）Yamaguchi K, Yoshida K, Tanahashi T, et al：The long-term survival of stage Ⅳ gastric cancer patients with conversion therapy. Gastric Cancer 21：315-323, 2017

7）Morgagni P, Solaini L, Framarini M, et al：Conversion surgery for gastric cancer：A cohort study from a western center. Int J Surg 53：360-365, 2018

8）Sato S, Kunisaki C, Tanaka Y, et al：Curative-intent surgery for stage Ⅳ advanced gastric cancer：who can undergo surgery and what are the prognostic factors for long-term survival? Ann Surg Oncol 26：4452-4463, 2019

9）Ohnuma H, Sato Y, Onoyama N, et al：Survival benefit of conversion surgery after intensive chemotherapy for unresectable metastatic gastric cancer：a propensity score-matching analysis. J Cancer Res Clin Oncol 147：2385-2396, 2021

10）Al-Batran SE, Goetze TO, Mueller DW, et al：The RENAISSANCE（AIO-FLOT5）trial：effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction-a phase Ⅲ trial of the German AIO/CAO-V/CAOGI. BMC Cancer 17：893, 2017

11）Folprecht G, Grothey A, Alberts S, et al：Neoadjuvant treatment of unresectable colorectal liver metastases：correlation between tumour response and resection rates. Ann Oncol 16：1311-1319, 2005

12）Janjigian YY, Shitara K, Moehler M, et al：First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma（CheckMate 649）：a randomised, open-label, phase 3 trial. Lancet 398：27-40, 2021

13）Bang YJ, Van Cutsem E, Feyereislova A, et al：Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase 3, open-label, randomised controlled trial. Lancet 376：687-697, 2010

14）Hayano K, Watanabe H, Ryuzaki T, et al：Prognostic benefit of conversion surgery for HER2 positive stage Ⅳ gastric cancer；a case series study of eleven patients treated with trastuzumab-based chemotherapy. Surg Case Rep 6：219, 2020

15）Arigami T, Matsushita D, Okubo K, et al：A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer. Surg Today 52：1721-1730, 2022

16）Takayama T, Sato Y, Sagawa T, et al：Phase Ⅰ study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Br J Cancer 97：851-856, 2007

17）Sato Y, Takayama T, Sagawa T, et al：Phase Ⅱ study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 66：721-728, 2010

18）Mitsui Y, Sato Y, Miyamoto H, et al：Trastuzumab in combination with docetaxel/cisplatin/S-1（DCS）for patients with HER2-positive metastatic gastric cancer：feasibility and preliminary efficacy. Cancer Chemother Pharmacol 76：375-382, 2015

19）Sato Y, Sagawa T, Ohnuma H, et al：A dose-escalation study of docetaxel, oxaliplatin, and S-1（DOS）as a first-line therapy for patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 83：161-167, 2019

20）Yamada Y, Boku N, Mizusawa J, et al：Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer（JCOG1013）：an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 4：501-510, 2019

21）Fukuchi M, Mochiki E, Ishiguro T, et al：Prognostic significance of conversion surgery following first- or second-line chemotherapy for unresectable gastric cancer. Anticancer Res 38：6473-6478, 2018

22）Cauchy F, Aussilhou B, Dokmak S, et al：Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Ann Surg 256：746-752, 2012

23）Ohnuma H, Sato Y, Hirakawa M, et al：Docetaxel, cisplatin and S-1（DCS）combination chemotherapy for gastric cancer patients with peritoneal metastasis：a retrospective study. Cancer Chemother Pharmacol 81：539-548, 2018

24）Ishigami H, Yamaguchi H, Yamashita H, et al：Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer 20：128-314, 2017